Metagenomi Therapeutics, Inc.

US$0.71As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:MGXHealthcare
Country USA
PE (Fwd) •••
TSR 3Y CAGR (64.88%)
Div yield —
ROE (60.61%)
Biotechnology
Beta (5Y) 0.83
PE TTM —
TSR TTM (72.07%)
Mkt cap US$26.80M
ROIC (32.31%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.901
27.06%
(19.66%)
Buy 4|1|2|12|6
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.01
0.01
0.01
0.01
9.85%
10.59%
26.23%
29.49%
Revenue$M
3.186
3.208
3.229
3.267
4.64%
2.17%
4.07%
5.40%
Peers (US$26.80M)
Cap (US$)
PE
25.74M
—
Capital
TTM
5Y
10Y
Leveragex
0.410
(0.109)
(0.095)
EBIT/Intx
1.696
0.288
0.304
Own earn%
(136.72)
(34.32)
(38.58)
Sh yield%
27.80
34.79
36.35
Owners
Insiders/Inst%
3.80
26.43
Short interest%
1.25
SBC / revenue%
1.27
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
13
Op margin range%
19–25
$1 testx
0.0
Incr. ROIC%
5